keyword
MENU ▼
Read by QxMD icon Read
search

Ozurdex

keyword
https://www.readbyqxmd.com/read/28524135/-selective-symptomatic-therapy-of-macular-edema-due-to-occlusive-processes-in-retinal-venous-system
#1
M M Bikbov, R R Fayzrakhmanov, T R Gil'manshin
AIM: to evaluate the effect of dexamethasone intravitreal implant on the functional state of the eye in macular edema associated with central retinal vein occlusion. MATERIAL AND METHODS: The study included two groups of patients: group 1 (control group) - 8 patients (16 eyes) without ocular pathology and group 2 (study group) - 8 patients (8 eyes) with macular edema on the background of newly diagnosed thrombosis of the central retinal vein. All the patients from the study group underwent insertion of an intravitreal dexamethasone implant - Ozurdex...
2017: Vestnik Oftalmologii
https://www.readbyqxmd.com/read/28492410/dexamethasone-intravitreal-implant-for-choroidal-neovascularization-during-pregnancy
#2
Vittorio Capuano, Rita Serra, Hassiba Oubraham, Olivia Zambrowski, Danielle Amana, Jennifer Zerbib, Eric H Souied, Giuseppe Querques
PURPOSE: To describe the management of active choroidal neovascularization (CNV) during pregnancy with the use of a dexamethasone intravitreal implant (DXI) (Ozurdex). METHODS: Case series of active CNV treated with DXI with at least 12-month follow-up retrospectively analyzed at 2 high-volume referral centers in France. Medical records and multimodal macular imaging were evaluated. RESULTS: Three eyes of 3 patients (age 30.0 ± 3.6 years) were included...
May 10, 2017: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/28489707/intravitreal-dexamethasone-ozurdex-implant-for-radiation-maculopathy-secondary-to-stereotactic-radiotherapy-for-posterior-uveal-melanoma
#3
Irem Koc, Sibel Kadayifcilar, Hayyam Kiratli, Bora Eldem
PURPOSE: To evaluate the efficacy of 0.7 mg intravitreal dexamethasone implant in the treatment of radiation maculopathy after stereotactic radiotherapy for posterior uveal melanoma. METHODS: Retrospective chart review of seven eyes of seven consecutive patients was performed. Extracted data included age, sex, initial and follow-up visual acuities and central macular thickness values, intraocular pressure, follow-up time, number of implants, and time elapsed from radiotherapy to implantation...
May 9, 2017: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/28463851/intravitreal-sustained-release-steroid-implants-for-the-treatment-of-macular-edema-following-surgical-removal-of-epiretinal-membranes
#4
Lars-Olof Hattenbach, Christina Springer-Wanner, Hans Hoerauf, Josep Callizo, Stephanie Jungmann, Thomas Brauns, Gergana Fulle, Sebastian Eichel, Michael Janusz Koss, Claudia Kuhli-Hattenbach
PURPOSE: To evaluate the efficacy of intravitreal dexamethasone implant for the treatment of postoperative persistent cystoid macular edema (CME) following macular pucker surgery. METHODS: In this multicenter study, we retrospectively reviewed the data of 37 patients (39 eyes) who had been treated with intravitreal dexamethasone implant (Ozurdex®) for persistent CME following macular pucker surgery. Main outcome measures were change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT)...
May 3, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28448238/single-dexamethasone-intravitreal-implant-in-the-treatment-of-noninfectious-uveitis
#5
Ariane Frère, Laure Caspers, Dorine Makhoul, Lia Judice, Laurence Postelmans, Xavier Janssens, Pierre Lefebvre, Christian Mélot, François Willermain
PURPOSE: To investigate the effect of a single intravitreal dexamethasone implant (IVT-DI; Ozurdex; Allergan, Inc.) on visual acuity, macular thickness, and intraocular pressure (IOP) in active noninfectious uveitis. METHODS: Medical records of patients with noninfectious active uveitis treated by IVT-DIs were retrospectively reviewed. Uveitis etiologies, treatment indications, best corrected visual acuity (BCVA), central retinal thickness measured by ocular coherence tomography, IOP, and systemic, local, and topical treatments were collected...
May 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28440260/immortal-ozurdex-a-10-month-follow-up-of-an-intralenticular-implant
#6
B Poornachandra, Vinod B M Kumar, Chaitra Jayadev, Subashchandra H Dorelli, Naresh Kumar Yadav, Rohit Shetty
A 78-year-old male who had received a dexamethasone implant (Ozurdex, Allergan, Inc., Irvine, CA, USA) 15 days back for recalcitrant diabetic macular edema in the left eye came to us for a second opinion. On examination, his corrected distance visual acuity was 20/20 in the right eye and 20/40 in the left eye. Early cataractous changes were present in both eyes. The intraocular pressure was within normal limits. The Ozurdex implant was seen lodged in the posterior cortex of the crystalline lens in the left eye, confirmed on anterior segment optical coherence tomography (OCT) and ultrasound biomicroscopy...
March 2017: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/28375791/intravitreal-dexamethasone-implant-for-treatment-of-serous-macular-detachment-in-central-retinal-vein-occlusion
#7
Ahmet Elbay, Hakan Ozdemir, Arif Koytak, Arif Melikov
PURPOSE: To evaluate the effect of intravitreal dexamethasone implant (Ozurdex) treatment on serous macular detachment (SMD) in patients with nonischemic central retinal vein occlusion (CRVO). METHODS: Retrospective, interventional, noncomparative case series was conducted. Twenty-four eyes of 24 patients with macular edema (ME) and SMD secondary to nonischemic CRVO made up the study population. Patients who had received intravitreal triamcinolone and/or antivascular endothelial growth factor treatment and/or had undergone retinal photocoagulation were excluded from the study...
April 4, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28360511/health-related-quality-of-life-visual-function-and-treatment-satisfaction-following-intravitreal-dexamethasone-implant-for-diabetic-macular-edema
#8
Jayashree Ramu, Irini Chatziralli, Yit Yang, Geeta Menon, Clare Bailey, Michael Eckstein, Phil Hykin, Sobha Sivaprasad
PURPOSE: The aim of this study was to explore and describe quantitatively patient-reported outcome measures (PROMs), ie, health-related quality of life (QoL), visual function and treatment satisfaction, in patients with diabetic macular edema (DME) receiving two different regimens of Ozurdex (intravitreal dexamethasone implant). METHODS: In this multicenter, prospective study, 100 patients with center-involving refractory DME were randomized 1:1 to either five monthly fixed dosing or optical coherence tomography (OCT)-guided pro re nata (PRN) regimen of dexamethasone intravitreal implant therapy...
2017: Patient Preference and Adherence
https://www.readbyqxmd.com/read/28336283/-early-efficacy-of-dexamethasone-implant-ozurdex-%C3%A2-in-diabetic-macular-edema-real-life-study
#9
V Sarda, F Fajnkuchen, S Nghiem-Buffet, T Grenet, G Chaine, A Giocanti-Auregan
PURPOSE: To assess early efficacy of dexamethasone intravitreal implant 0.7mg (OZURDEX(®)) at the time of peak efficacy (2 months after injection) in patients with decreased visual acuity secondary to diabetic macular edema (DME). MATERIALS AND METHODS: Retrospective monocentric study. Inclusion criteria were best-corrected visual acuity (BCVA)≤70 letters (20/40) due to DME and central retinal thickness (CRT)≥300 microns (Cirrus 2, Carl Zeiss Meditec, Inc, Dublin)...
May 2017: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/28334720/intravitreal-dexamethasone-implant-versus-intravitreal-ranibizumab-for-the-treatment-of-macular-edema-secondary-to-retinal-vein-occlusion-in-a-chinese-population
#10
Xiaoya Gu, Xiaobing Yu, Shuang Song, Hong Dai
BACKGROUND: The aim of this work was to compare the efficacy of intravitreal dexamethasone implant (Ozurdex) and intravitreal ranibizumab (Lucentis) in the treatment of macular edema (ME) caused by retinal vein occlusion (RVO). METHODS: Thirty-two ME cases treated with Ozurdex and 32 ME cases treated with ranibizumab were enrolled, with 26 central (C)RVO and 6 branch (B)RVO subjects in each group. We compared the results of best-corrected visual acuity (BCVA), central retinal thickness, number of injections, and intraocular pressure (IOP) at 1, 2, 3, and 6 months after injection...
March 24, 2017: Ophthalmic Research
https://www.readbyqxmd.com/read/28318718/-treatment-of-macular-edema-comparison-of-efficacy-and-tolerability-of-subconjunctival-triamcinolone-injections-sub-tenon-s-triamcinolone-injections-and-intravitreal-dexamethasone-implant
#11
C Carbonnière, C Couret, A Blériot, O Lebreton, H Massé, G Le Meur, P Lebranchu, M Weber
The area of uveitis is related to numerous pathological entities. One of the main causes of decreased visual acuity in these patients is macular edema. One aspect of the treatment includes cortosteroids used peri- and intra-ocularly. MATERIALS AND METHODS: The goal of our work was to estimate the criteria of efficacy (on improvement in visual acuity and macular edema, as well as time to recurrence) and safety (on intraocular pressure and cataract) of these various routes of administration of corticosteroid after a single injection...
March 16, 2017: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/28237428/slow-release-dexamethasone-in-proliferative-vitreoretinopathy-a-prospective-randomized-controlled-clinical-trial
#12
Philip J Banerjee, Ana Quartilho, Catey Bunce, Wen Xing, Tapiwa M Zvobgo, Nicola Harris, David G Charteris
PURPOSE: To test the hypothesis that adjunctive slow-release dexamethasone implant (Ozurdex; Allergan Inc, Irvine, CA) can improve the outcomes of vitreoretinal surgery for established proliferative vitreoretinopathy (PVR). DESIGN: A 2-year, single-center, prospective, participant- and surgeon-masked randomized controlled clinical trial (EudraCT No. 2011-004498-96). PARTICIPANTS: A total of 140 patients requiring vitrectomy surgery with silicone oil for retinal detachment with established PVR (Grade C) were randomized to standard (control) or study treatment (adjunct) in a 1:1 allocation ratio...
February 22, 2017: Ophthalmology
https://www.readbyqxmd.com/read/28218368/intravitreal-dexamethasone-implant-ozurdex%C3%A2-for-exudative-retinal-detachment-after-proton-beam-therapy-for-choroidal-melanoma
#13
Ariane Malclès, Anh-Minh Nguyen, Thibaud Mathis, Jean-Daniel Grange, Laurent Kodjikian
PURPOSE: To evaluate the efficacy and safety of intravitreal 0.7-mg dexamethasone implant (DEX-I) (Ozurdex®) in the treatment of extensive exudative retinal detachment (RD) associated with uveal melanoma treated using proton beam therapy (PBT). METHODS: Data from 10 patients with exudative RD after PBT treated with intravitreal injection of 0.7-mg DEX-I were reviewed retrospectively. The main outcome measures were resolution of exudative RD, visual acuity, and safety profile...
February 8, 2017: European Journal of Ophthalmology
https://www.readbyqxmd.com/read/28196056/effect-of-an-intravitreal-dexamethasone-implant-on-diabetic-macular-edema-after-cataract-surgery
#14
Pilar Calvo, Antonio Ferreras, Fadwa Al Adel, Wantanee Dangboon, Michael H Brent
PURPOSE: To analyze the effects of a dexamethasone intravitreal implant (DEX; Ozurdex 700 μg; Allergan) administered immediately after cataract surgery in diabetic patients. METHODS: This prospective, single-arm, open label study (NCT01748487 at ClinicalTrials.gov) involved Type 2 diabetic patients with at least mild diabetic retinopathy (DR) who underwent cataract surgery and DEX insertion after phacoemulsification, and intraocular lens implantation were enrolled...
February 10, 2017: Retina
https://www.readbyqxmd.com/read/28195619/efficacy-of-the-intravitreal-sustained-release-dexamethasone-implant-for-diabetic-macular-edema-refractory-to-anti-vascular-endothelial-growth-factor-therapy-meta-analysis-and-clinical-implications
#15
Zainab Khan, Robin K Kuriakose, Maryam Khan, Eric K Chin, David R P Almeida
BACKGROUND AND OBJECTIVE: To assess the effect on best-corrected visual acuity (BCVA) and efficacy of the intravitreal sustained-release 0.7 mg dexamethasone implant (Ozurdex; Allergan, Irvine, CA) in patients with recalcitrant diabetic macular edema (DME). PATIENTS AND METHODS: Meta-analysis utilizing the MOOSE framework and a random effects model. Studies included adults undergoing treatment with Ozurdex for DME. The methodologic quality of each study was assessed using the MINORS and the Cochrane Collaboration Risk of Bias for randomized studies...
February 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28147403/intraocular-dexamethasone-implant-as-adjunct-to-silicone-oil-tamponade-for-proliferative-vitreoretinopathy
#16
M Sherif, T J Wolfensberger
Background Proliferative vitreoretinopathy (PVR) occurs in 10 % of patients with retinal detachment and is characterized by excessive epi-, sub- or intraretinal contraction. Corticosteroids have been shown to counter this contraction. Patients and Methods Retrospective review of 5 patients (3 females, 2 males) with recurrent retinal detachment with stage C PVR. The mean age was 61.2 ± 20.5 years and myopia > - 5.0 dioptres was present in 3 eyes. Patients were treated with 23 g vitrectomy, retinectomy and endolaser, dexamethasone (Ozurdex®) injection under perfluorocarbone and 5500 cs silicone oil tamponade...
April 2017: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/28139100/dexamethasone-implant-with-fixed-or-individualized-regimen-in-the-treatment-of-diabetic-macular-oedema-six-month-outcomes-of-the-udbasa-study
#17
Valentina Sarao, Daniele Veritti, Claudio Furino, Ermete Giancipoli, Giovanni Alessio, Francesco Boscia, Paolo Lanzetta
PURPOSE: To evaluate a pro re nata administration of Ozurdex(®) implant versus a single administration for treating diabetic macular oedema (DME). METHODS: This exploratory study is designed as a comparative, multicentre, randomized study with a follow-up of 6 months. Patients with DME were assigned to treatment at baseline either with a single Ozurdex(®) implant during the entire six-month follow-up (fixed group) or Ozurdex(®) implant followed by retreatment on an individualized basis (PRN group)...
January 31, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/28058154/intravitreal-dexamethasone-implant-ozurdex-for-refractory-macular-edema-secondary-to-retinitis-pigmentosa
#18
Nurgül Örnek, Kemal Örnek, İnci Elif Erbahçeci
Macular edema (ME) in retinitis pigmentosa (RP) often impairs central vision dramatically. A 41-year-old woman diagnosed with RP was referred to our outpatient clinic due to severe visual deterioration in both eyes. The patient was treated with topical carbonic anhydrase inhibitors, topical corticosteroids and intravitreal triamcinolone acetonide injections, but her ME recurred. Intravitreal 0.7 mg dexamethasone implant (Ozurdex, Allergan) was administered into both eyes without complications. On the fourth day after both injections, visual acuity improved and ME almost totally resolved...
August 2016: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/28031700/long-term-results-of-combination-therapy-using-anti-vegf-agents-and-dexamethasone-intravitreal-implant-for-retinal-vein-occlusion-an-investigational-case-series
#19
Michael A Singer, Michael E Jansen, Lyndon Tyler, Paul Woods, Faisal Ansari, Udit Jain, Joshua Singer, Darren Bell, Chelsey Krambeer
BACKGROUND: One limitation of anti-VEGF therapy is the need for monthly retreatment to maintain efficacy. The purpose of this study was to determine the duration of effect in eyes with macular edema (ME) secondary to branch or central retinal vein occlusion (BRVO or CRVO) treated with anti-VEGF therapy plus sustained-release dexamethasone (DEX implant; Ozurdex). MATERIALS AND METHODS: This open-label, interventional case series included 62 eyes with ME due to RVO, central foveal thickness (CFT) >300 μm, and best-corrected visual acuity (BCVA) of 20/40 or worse...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28017484/choroidal-haemangioma-and-photodynamic-therapy-anatomical-and-functional-response-of-patients-with-choroidal-hemangioma-treated-with-photodynamic-therapy
#20
O Subirà, H Brosa, D Lorenzo-Parra, L Arias-Barquet, J Català-Mora, E Cobos, P Garcia-Bru, M J Rubio-Caso, J M Caminal-Mitjana
OBJECTIVE: To study the effectiveness and limitations of photodynamic therapy (PDT) as treatment of choice in patients with symptomatic circumscribed choroidal haemangioma. METHODS: A retrospective study was conducted on 16 patients (13 men and 3 women, with mean age of 54.88 years) with circumscribed choroidal haemangioma, who attended our centre and were treated with PDT in the last 7 years. RESULTS: All patients had circumscribed choroidal haemangioma, which caused a decrease in visual acuity (VA) secondary to the presence of intraretinal microcystic oedema or neurosensory detachment...
December 22, 2016: Archivos de la Sociedad Española de Oftalmología
keyword
keyword
33543
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"